NCT00435279View on ClinicalTrials.gov

A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

PHASE3CompletedINTERVENTIONAL
Enrollment

678

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Major Depressive DisorderInsomnia
Interventions
DRUG

Eszopiclone

Eszopiclone 3 mg

DRUG

Placebo

Placebo

DRUG

Venlafaxine

Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28

Trial Locations (69)

1083

Budapest

1134

Budapest

1135

Budapest

2660

Balassagyarmat

2700

Cegléd

4412

Nyíregyháza

10090

Zagreb

11000

Belgrade

14000

Caen

18000

Niš

21005

Vinnitsa

31000

Toulouse

31300

Toulouse

35000

Rennes

49005

Dnipro

65000

Odesa

67100

Strasbourg

78000

Verasailles

78230

Le Pecq

78990

Élancourt

79021

Lviv

83037

Donetsk

95006

Crimea

107076

Moscow

115522

Moscow

125367

Moscow

163001

Arkhangelsk

190121

Saint Petersburg

191180

Saint Petersburg

192019

Saint Petersburg

194044

Saint Petersburg

197341

Saint Petersburg

198020

Saint Petersburg

355108

Stavropol

410154

Oradea

700282

Lasi

Unknown

Salzburg

Arcachon

Savigny-sur-Orge

Toulouse

Bydgoszcz

Niš

Coventry

A-1010

Vienna

A-1090

Vienna

21 000

Split

Novi Sad

10 000

Zagreb

97-400

Bełchatów

31-530

Krakow

90-130

Lodz

20-109

Lublin

87-100

Torun

95-080

Tuszyn

041902

Bucharest

91-400

Belchatow

11 000

Belgrade

34 000

Kragujevac

02660

Kiev

03049

Kiev

04080

Kiev

BA 1 2SR

Avon

G51 4TF

Glasgow

PL23 1DT

Fowey

G20 OXA

Glasgow

HA13UJ

Harrow

RH16 4BE

Haywards Heath

PL6 7TH

Plymouth

CV32 4RA

Warks

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00435279 - A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia | Biotech Hunter | Biotech Hunter